Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

Moderna announced July 10 that the FDA had fully approved its Spikevax COVID vaccine for kids ages 6 months through 11 years ...